Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-12-19 06:45:00
Oslo, Norway, December 19, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that it has entered into a
strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to
supply plasmid DNA for Nykode's wholly owned and partnered product portfolio.
"We are excited about the strategic manufacturing partnership with Richter-Helm
BioLogics. As a leading manufacturer of DNA vaccines, they will provide the
long-term expertise and capacity needed to support our ambitious growth and
pipeline development," stated Mette Husbyn, Chief Technology Officer of Nykode
Therapeutics.
"We are thrilled to collaborate with Nykode Therapeutics and to support the
development of their leading DNA vaccine platform. After 30 years of
manufacturing plasmid DNA, we have gained an unparalleled amount of first-hand
plasmid DNA process knowledge and experience working with regulatory agencies to
ensure cGMP compliance for clinical trials and late-stage product candidates,"
said Dr. Kai Pohlmeyer, Managing Director of Richter-Helm BioLogics.
Manufacturing is a strategic focus area for Nykode and its license partners.
Under the partnership agreement with Richter-Helm BioLogics, Nykode will have
the option to tech transfer the proprietary manufacturing processes to its
partners, if requested.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase 2 trial
for the treatment of cervical cancer